\relax 
\providecommand\hyper@newdestlabel[2]{}
\providecommand\HyperFirstAtBeginDocument{\AtBeginDocument}
\HyperFirstAtBeginDocument{\ifx\hyper@anchor\@undefined
\global\let\oldcontentsline\contentsline
\gdef\contentsline#1#2#3#4{\oldcontentsline{#1}{#2}{#3}}
\global\let\oldnewlabel\newlabel
\gdef\newlabel#1#2{\newlabelxx{#1}#2}
\gdef\newlabelxx#1#2#3#4#5#6{\oldnewlabel{#1}{{#2}{#3}}}
\AtEndDocument{\ifx\hyper@anchor\@undefined
\let\contentsline\oldcontentsline
\let\newlabel\oldnewlabel
\fi}
\fi}
\global\let\hyper@last\relax 
\gdef\HyperFirstAtBeginDocument#1{#1}
\providecommand\HyField@AuxAddToFields[1]{}
\providecommand\HyField@AuxAddToCoFields[2]{}
\providecommand\BKM@entry[2]{}
\bibstyle{WileyNJD-AMA}
\BKM@entry{id=1,open,dest={446F632D5374617274},srcline={49}}{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}
\BKM@entry{id=2,open,dest={446F632D5374617274},srcline={49}}{5C3337365C3337375C303030415C303030625C303030735C303030745C303030725C303030615C303030635C30303074}
\BKM@entry{id=3,open,dest={73656374696F6E2E31},srcline={54}}{5C3337365C3337375C303030495C3030306E5C303030745C303030725C3030306F5C303030645C303030755C303030635C303030745C303030695C3030306F5C3030306E}
\citation{world2014global}
\citation{bokhorst2015compliance}
\citation{weusten2017endoscopic}
\citation{krist2007timing}
\citation{mcwilliams2008surveillance}
\citation{krist2007timing,mcwilliams2008surveillance,bokhorst2015compliance}
\citation{krist2007timing,loeb2013systematic}
\citation{bokhorst2015compliance,LeClercq2015325}
\@writefile{toc}{\contentsline {chapter}{Shared Decision Making of Burdensome Surveillance Tests Using Personalized Schedules and Their Burden and Benefit\thanks  {The authors gratefully acknowledge Nederlandse Organisatie voor Wetenschappelijk Onderzoek VIDI grant nr. 016.146.301, and Erasmus University Medical Center funding}}{1}{Doc-Start}\protected@file@percent }
\Newlabel{1}{1}
\Newlabel{2}{2}
\Newlabel{3}{3}
\Newlabel{4}{4}
\@writefile{toc}{\contentsline {section}{Abstract}{1}{Doc-Start}\protected@file@percent }
\citation{bokhorst2015compliance,weusten2017endoscopic}
\citation{alagoz2010operations,steimle2017markov}
\citation{vickers2006decision}
\citation{tomer2019personalizedbiometrics}
\citation{bebu2017optimal}
\citation{vickers2006decision,rizopoulos2015personalized}
\citation{tomer2019personalized}
\citation{wang2019learning}
\citation{tomer2019personalizedbiometrics,tomer2019personalized}
\citation{tomer2019personalized}
\citation{wang2019learning}
\citation{bebu2017optimal}
\@writefile{toc}{\contentsline {section}{\numberline {1}Introduction}{2}{section.1}\protected@file@percent }
\newlabel{sec:introduction}{{1}{2}{Introduction}{section.1}{}}
\citation{tsiatis2004joint,rizopoulos2012joint}
\citation{mcculloch2005generalized}
\@writefile{lof}{\contentsline {figure}{\numberline {1}{\ignorespaces \textbf  {Goal: Finding the optimal tradeoff between the number of invasive tests (burden) and time delay in detecting progression (shorter is beneficial)}. A progression is a non-terminal event in the surveillance of early-stage chronic non-communicable diseases. The true time of progression for the patient illustrated in this figure is July 2004. Since invasive tests are conducted repeatedly, progression is interval-censored and always observed with a delay. Frequent periodical invasive tests in \textbf  {Panel\nobreakspace  {}A} lead to a shorter time delay in detecting progression than infrequent periodical invasive tests in \textbf  {Panel\nobreakspace  {}B}. The interval-censored time of progression is Jan\nobreakspace  {}2004--Jan\nobreakspace  {}2005 in \textbf  {Panel\nobreakspace  {}A} and between Jan\nobreakspace  {}2004--Jan\nobreakspace  {}2006 in \textbf  {Panel\nobreakspace  {}B}.\relax }}{3}{figure.caption.1}\protected@file@percent }
\providecommand*\caption@xref[2]{\@setref\relax\@undefined{#1}}
\newlabel{fig:figure1}{{1}{3}{\textbf {Goal: Finding the optimal tradeoff between the number of invasive tests (burden) and time delay in detecting progression (shorter is beneficial)}. A progression is a non-terminal event in the surveillance of early-stage chronic non-communicable diseases. The true time of progression for the patient illustrated in this figure is July 2004. Since invasive tests are conducted repeatedly, progression is interval-censored and always observed with a delay. Frequent periodical invasive tests in \textbf {Panel~A} lead to a shorter time delay in detecting progression than infrequent periodical invasive tests in \textbf {Panel~B}. The interval-censored time of progression is Jan~2004--Jan~2005 in \textbf {Panel~A} and between Jan~2004--Jan~2006 in \textbf {Panel~B}.\relax }{figure.caption.1}{}}
\citation{bokhorst2015compliance}
\citation{loeb2014overdiagnosis}
\citation{epsteinGG2014}
\citation{loeb2014heterogeneity}
\citation{bokhorst2015compliance}
\citation{GlobalCancerStats2012}
\BKM@entry{id=4,open,dest={73656374696F6E2E32},srcline={79}}{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}
\BKM@entry{id=5,open,dest={73756273656374696F6E2E322E31},srcline={83}}{5C3337365C3337375C3030304C5C3030306F5C3030306E5C303030675C303030695C303030745C303030755C303030645C303030695C3030306E5C303030615C3030306C5C3030305C3034305C303030535C303030755C303030625C3030302D5C303030705C303030725C3030306F5C303030635C303030655C303030735C30303073}
\citation{mcculloch2005generalized}
\BKM@entry{id=6,open,dest={73756273656374696F6E2E322E32},srcline={92}}{5C3337365C3337375C303030535C303030755C303030725C303030765C303030695C303030765C303030615C3030306C5C3030305C3034305C303030535C303030755C303030625C3030302D5C303030705C303030725C3030306F5C303030635C303030655C303030735C30303073}
\citation{brown2009assessing,rizopoulos2012joint,taylor2013real}
\citation{eilers1996flexible}
\@writefile{toc}{\contentsline {section}{\numberline {2}Joint Model for Time-to-Progression and Longitudinal Outcomes}{4}{section.2}\protected@file@percent }
\newlabel{sec:jointmodel}{{2}{4}{Joint Model for Time-to-Progression and Longitudinal Outcomes}{section.2}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.1}Longitudinal Sub-process}{4}{subsection.2.1}\protected@file@percent }
\newlabel{eq:long_model}{{2.1}{4}{Longitudinal Sub-process}{subsection.2.1}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.2}Survival Sub-process}{4}{subsection.2.2}\protected@file@percent }
\newlabel{subsec:surival_sub_model}{{2.2}{4}{Survival Sub-process}{subsection.2.2}{}}
\newlabel{eq:rel_risk_model}{{2.2}{4}{Survival Sub-process}{subsection.2.2}{}}
\BKM@entry{id=7,open,dest={73656374696F6E2E33},srcline={111}}{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}
\BKM@entry{id=8,open,dest={73756273656374696F6E2E332E31},srcline={114}}{5C3337365C3337375C303030435C303030755C3030306D5C303030755C3030306C5C303030615C303030745C303030695C303030765C303030655C3030302D5C303030725C303030695C303030735C3030306B5C3030305C3034305C3030306F5C303030665C3030305C3034305C303030705C303030725C3030306F5C303030675C303030725C303030655C303030735C303030735C303030695C3030306F5C3030306E}
\BKM@entry{id=9,open,dest={73756273656374696F6E2E332E32},srcline={133}}{5C3337365C3337375C303030505C303030655C303030725C303030735C3030306F5C3030306E5C303030615C3030306C5C303030695C3030307A5C303030655C303030645C3030305C3034305C303030545C303030655C303030735C303030745C3030305C3034305C303030445C303030655C303030635C303030695C303030735C303030695C3030306F5C3030306E5C3030305C3034305C303030525C303030755C3030306C5C30303065}
\citation{tomer2019personalizedbiometrics,tomer2019personalized}
\@writefile{toc}{\contentsline {section}{\numberline {3}Personalized Schedule of Invasive Tests for Detecting Progression}{5}{section.3}\protected@file@percent }
\newlabel{sec:schedule}{{3}{5}{Personalized Schedule of Invasive Tests for Detecting Progression}{section.3}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.1}Cumulative-risk of progression}{5}{subsection.3.1}\protected@file@percent }
\newlabel{subsec:cum_risk}{{3.1}{5}{Cumulative-risk of progression}{subsection.3.1}{}}
\newlabel{eq:cumulative_risk}{{1}{5}{Cumulative-risk of progression}{equation.3.1}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.2}Personalized Test Decision Rule}{5}{subsection.3.2}\protected@file@percent }
\newlabel{subsec:pers_schedule}{{3.2}{5}{Personalized Test Decision Rule}{subsection.3.2}{}}
\newlabel{eq:personalized_decision_grid}{{2}{5}{Personalized Test Decision Rule}{equation.3.2}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {2}{\ignorespaces \textbf  {The cumulative-risk function (\ref  {eq:cumulative_risk}) is time-dynamic} because it automatically updates over time as more longitudinal and invasive test result data becomes available. We illustrate this using a single longitudinal outcome, namely, a continuous biomarker of disease progression (All values are illustrative). \textbf  {Panels\nobreakspace  {}A,\nobreakspace  {}B\nobreakspace  {}and\nobreakspace  {}C} are ordered by the time of the current visit $v$ (dashed vertical black line) of a new patient. At each of these visits, we combine the accumulated longitudinal data (shown in blue circles), and time of the last negative invasive test $t$ (solid vertical green line) to obtain the updated cumulative-risk profile $R_j(u \mid t, v)$ (dotted red line with 95\% credible interval shaded) of the patient. The benefit of this time-dynamic property is that the resulting schedules in Section \ref  {subsec:pers_schedule} and their estimated burden and benefit in Section \ref  {subsec:exp_delay_estimation} are also time-dynamic.\relax }}{6}{figure.caption.2}\protected@file@percent }
\newlabel{fig:figure2}{{2}{6}{\textbf {The cumulative-risk function (\ref {eq:cumulative_risk}) is time-dynamic} because it automatically updates over time as more longitudinal and invasive test result data becomes available. We illustrate this using a single longitudinal outcome, namely, a continuous biomarker of disease progression (All values are illustrative). \textbf {Panels~A,~B~and~C} are ordered by the time of the current visit $v$ (dashed vertical black line) of a new patient. At each of these visits, we combine the accumulated longitudinal data (shown in blue circles), and time of the last negative invasive test $t$ (solid vertical green line) to obtain the updated cumulative-risk profile $R_j(u \mid t, v)$ (dotted red line with 95\% credible interval shaded) of the patient. The benefit of this time-dynamic property is that the resulting schedules in Section \ref {subsec:pers_schedule} and their estimated burden and benefit in Section \ref {subsec:exp_delay_estimation} are also time-dynamic.\relax }{figure.caption.2}{}}
\BKM@entry{id=10,open,dest={73756273656374696F6E2E332E33},srcline={162}}{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}
\@writefile{lof}{\contentsline {figure}{\numberline {3}{\ignorespaces \textbf  {Successive personalized test decisions based on patient-specific cumulative-risk of progression (\ref  {eq:personalized_decision_grid})}. Time of current visit: $v=2.5$ years (dashed vertical black line). Time of the last test on which progression was not observed: $t=1.5$ years. Longitudinal data up to current visit: $\mathcal  {Y}_j(v)$ is a continuous biomarker (blue circles). Example risk threshold: $\kappa =0.12$\nobreakspace  {}(12\%). Grid of future visits on which future tests are planned: $U = \{2.5, 3.5, 4.5, 5.5, 6.5\}$ years. The cumulative-risk profiles $R_j(u_l \mid t_l, v)$ employed in\nobreakspace  {}(\ref  {eq:personalized_decision_grid}) are shown with dotted red lines (95\% credible intervals shaded), and are updated each time a test is planned (solid vertical green lines). Future test decisions $Q_j(u_l \mid t_l, v)$ defined in\nobreakspace  {}(\ref  {eq:personalized_decision_grid}) are: $Q_j^\kappa (u_1=2.5\mid t_1=1.5,v)=0$, $Q_j^\kappa (u_2=3.5\mid t_2=1.5,v)=1$, $Q_j^\kappa (u_3=4.5\mid t_3=3.5,v)=0$, $Q_j^\kappa (u_4=5.5\mid t_4=3.5,v)=1$, and $Q_j^\kappa (u_5=6.5\mid t_5=5.5,v)=0$. All values are illustrative.\relax }}{7}{figure.caption.3}\protected@file@percent }
\newlabel{fig:figure3}{{3}{7}{\textbf {Successive personalized test decisions based on patient-specific cumulative-risk of progression (\ref {eq:personalized_decision_grid})}. Time of current visit: $v=2.5$ years (dashed vertical black line). Time of the last test on which progression was not observed: $t=1.5$ years. Longitudinal data up to current visit: $\mathcal {Y}_j(v)$ is a continuous biomarker (blue circles). Example risk threshold: $\kappa =0.12$~(12\%). Grid of future visits on which future tests are planned: $U = \{2.5, 3.5, 4.5, 5.5, 6.5\}$ years. The cumulative-risk profiles $R_j(u_l \mid t_l, v)$ employed in~(\ref {eq:personalized_decision_grid}) are shown with dotted red lines (95\% credible intervals shaded), and are updated each time a test is planned (solid vertical green lines). Future test decisions $Q_j(u_l \mid t_l, v)$ defined in~(\ref {eq:personalized_decision_grid}) are: $Q_j^\kappa (u_1=2.5\mid t_1=1.5,v)=0$, $Q_j^\kappa (u_2=3.5\mid t_2=1.5,v)=1$, $Q_j^\kappa (u_3=4.5\mid t_3=3.5,v)=0$, $Q_j^\kappa (u_4=5.5\mid t_4=3.5,v)=1$, and $Q_j^\kappa (u_5=6.5\mid t_5=5.5,v)=0$. All values are illustrative.\relax }{figure.caption.3}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.3}Expected Number of Tests and Expected Time Delay in Detecting Progression}{8}{subsection.3.3}\protected@file@percent }
\newlabel{subsec:exp_delay_estimation}{{3.3}{8}{Expected Number of Tests and Expected Time Delay in Detecting Progression}{subsection.3.3}{}}
\newlabel{eq:personalized_schedule_grid}{{3}{8}{Expected Number of Tests and Expected Time Delay in Detecting Progression}{equation.3.3}{}}
\newlabel{eq:exp_tests}{{4}{8}{Expected Number of Tests and Expected Time Delay in Detecting Progression}{equation.3.4}{}}
\newlabel{eq:exp_delay}{{5}{8}{Expected Number of Tests and Expected Time Delay in Detecting Progression}{equation.3.5}{}}
\BKM@entry{id=11,open,dest={73756273656374696F6E2E332E34},srcline={214}}{5C3337365C3337375C303030485C3030306F5C303030775C3030305C3034305C303030745C3030306F5C3030305C3034305C303030535C303030655C3030306C5C303030655C303030635C303030745C3030305C3034305C303030745C303030685C303030655C3030305C3034305C303030525C303030695C303030735C3030306B5C3030305C3034305C303030545C303030685C303030725C303030655C303030735C303030685C3030306F5C3030306C5C303030645C3030305C303430}
\citation{cook1994equivalence}
\citation{sassi2006calculating}
\citation{de2017should}
\BKM@entry{id=12,open,dest={73656374696F6E2E34},srcline={234}}{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}
\citation{rizopoulosJMbayes}
\citation{landmarking2017}
\citation{landmarking2017}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.4}How to Select the Risk Threshold $\kappa $}{9}{subsection.3.4}\protected@file@percent }
\newlabel{subsec:kappa_selection}{{3.4}{9}{How to Select the Risk Threshold $\kappa $}{subsection.3.4}{}}
\newlabel{eq:kappa_choice}{{6}{9}{How to Select the Risk Threshold $\kappa $}{equation.3.6}{}}
\@writefile{toc}{\contentsline {section}{\numberline {4}Application of Personalized Schedules in Prostate Cancer Surveillance}{9}{section.4}\protected@file@percent }
\newlabel{sec:results}{{4}{9}{Application of Personalized Schedules in Prostate Cancer Surveillance}{section.4}{}}
\BKM@entry{id=13,open,dest={73756273656374696F6E2E342E31},srcline={240}}{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}
\citation{bokhorst2015compliance}
\citation{carvalho}
\@writefile{lof}{\contentsline {figure}{\numberline {4}{\ignorespaces \textbf  {Optimal current-visit time $v$ specific risk threshold $\kappa ^*(v)$ obtained using\nobreakspace  {}(\ref  {eq:kappa_choice})} for the patient shown in Figure\nobreakspace  {}\ref  {fig:figure3}. Ideal schedule of tests: point (1,0) shown as a blue square. It plans exactly one invasive test at the true time of progression $T^*_j$ of a patient. Hence, the time delay in detecting progression is zero. Various personalized schedules based on a grid of thresholds $\kappa \in [0, 1]$ are shown with black circles. Higher thresholds lead to fewer tests, but also higher expected time delay. The personalized schedule based on $\kappa ^*(v)=9.5\%$ threshold (green triangle) has the least Euclidean distance (solid green line) to the ideal schedule. It is also possible to optimize the least distance under a certain clinically acceptable limit on the time delay (dotted horizontal orange line).\relax }}{10}{figure.caption.4}\protected@file@percent }
\newlabel{fig:figure4}{{4}{10}{\textbf {Optimal current-visit time $v$ specific risk threshold $\kappa ^*(v)$ obtained using~(\ref {eq:kappa_choice})} for the patient shown in Figure~\ref {fig:figure3}. Ideal schedule of tests: point (1,0) shown as a blue square. It plans exactly one invasive test at the true time of progression $T^*_j$ of a patient. Hence, the time delay in detecting progression is zero. Various personalized schedules based on a grid of thresholds $\kappa \in [0, 1]$ are shown with black circles. Higher thresholds lead to fewer tests, but also higher expected time delay. The personalized schedule based on $\kappa ^*(v)=9.5\%$ threshold (green triangle) has the least Euclidean distance (solid green line) to the ideal schedule. It is also possible to optimize the least distance under a certain clinically acceptable limit on the time delay (dotted horizontal orange line).\relax }{figure.caption.4}{}}
\citation{carvalho}
\citation{carvalho}
\BKM@entry{id=14,open,dest={73656374696F6E2E35},srcline={254}}{5C3337365C3337375C303030535C303030695C3030306D5C303030755C3030306C5C303030615C303030745C303030695C3030306F5C3030306E5C3030305C3034305C303030535C303030745C303030755C303030645C30303079}
\BKM@entry{id=15,open,dest={73756273656374696F6E2E352E31},srcline={258}}{5C3337365C3337375C303030535C303030695C3030306D5C303030755C3030306C5C303030615C303030745C303030695C3030306F5C3030306E5C3030305C3034305C303030535C303030655C303030745C303030755C30303070}
\citation{bokhorst2015compliance}
\BKM@entry{id=16,open,dest={73756273656374696F6E2E352E32},srcline={263}}{5C3337365C3337375C303030535C303030695C3030306D5C303030755C3030306C5C303030615C303030745C303030695C3030306F5C3030306E5C3030305C3034305C303030525C303030655C303030735C303030755C3030306C5C303030745C30303073}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.1}Personalized Biopsy Schedules for a Demonstration Patient}{11}{subsection.4.1}\protected@file@percent }
\newlabel{subsec:demo_patient}{{4.1}{11}{Personalized Biopsy Schedules for a Demonstration Patient}{subsection.4.1}{}}
\@writefile{toc}{\contentsline {section}{\numberline {5}Simulation Study}{11}{section.5}\protected@file@percent }
\newlabel{sec:sim_study}{{5}{11}{Simulation Study}{section.5}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {5.1}Simulation Setup}{11}{subsection.5.1}\protected@file@percent }
\citation{inoue2018comparative}
\citation{carvalho}
\@writefile{lof}{\contentsline {figure}{\numberline {5}{\ignorespaces \textbf  {Personalized schedules for a demonstration prostate cancer patient}. \textbf  {Panel\nobreakspace  {}A}: Time of current visit: $v=5$ years (black dashed line). Time of last negative biopsy: $t=3.5$ years (vertical green solid line). Longitudinal data: $\qopname  \relax o{log}_2(\mbox  {PSA} + 1)$ transformed PSA (observed: blue dots, fitted: solid blue line), and binary DRE (observed: blue triangles, fitted probability: solid blue line). Cumulative-risk profile: dotted red line (95\% credible interval shaded). \textbf  {Panel\nobreakspace  {}B}: Biopsy indicated with a `B', and \textbf  {$\kappa =10\%$} and \textbf  {$\kappa ^*(v)$} are personalized biopsy schedules using a risk threshold of 10\%, and a visit time $v$ specific automatically chosen threshold\nobreakspace  {}(\ref  {eq:kappa_choice}), respectively. PRIAS and Annual denote the PRIAS biopsy schedule (Section\nobreakspace  {}\ref  {subsec:demo_patient}) and annual biopsy schedule. \textbf  {Panel\nobreakspace  {}C,D}: For all schedules we calculate the expected number of tests and expected time delay in detecting progression if the patient progresses before year ten. Since a recommended minimum gap of one year is maintained between biopsies, maximum possible number of tests are six. A delay in detecting progression of up to three years may not lead to adverse outcomes\nobreakspace  {}\citep  {carvalho}.\relax }}{12}{figure.caption.5}\protected@file@percent }
\newlabel{fig:figure5}{{5}{12}{\textbf {Personalized schedules for a demonstration prostate cancer patient}. \textbf {Panel~A}: Time of current visit: $v=5$ years (black dashed line). Time of last negative biopsy: $t=3.5$ years (vertical green solid line). Longitudinal data: $\log _2(\mbox {PSA} + 1)$ transformed PSA (observed: blue dots, fitted: solid blue line), and binary DRE (observed: blue triangles, fitted probability: solid blue line). Cumulative-risk profile: dotted red line (95\% credible interval shaded). \textbf {Panel~B}: Biopsy indicated with a `B', and \textbf {$\kappa =10\%$} and \textbf {$\kappa ^*(v)$} are personalized biopsy schedules using a risk threshold of 10\%, and a visit time $v$ specific automatically chosen threshold~(\ref {eq:kappa_choice}), respectively. PRIAS and Annual denote the PRIAS biopsy schedule (Section~\ref {subsec:demo_patient}) and annual biopsy schedule. \textbf {Panel~C,D}: For all schedules we calculate the expected number of tests and expected time delay in detecting progression if the patient progresses before year ten. Since a recommended minimum gap of one year is maintained between biopsies, maximum possible number of tests are six. A delay in detecting progression of up to three years may not lead to adverse outcomes~\citep {carvalho}.\relax }{figure.caption.5}{}}
\@writefile{toc}{\contentsline {subsection}{\numberline {5.2}Simulation Results}{12}{subsection.5.2}\protected@file@percent }
\BKM@entry{id=17,open,dest={73656374696F6E2E36},srcline={276}}{5C3337365C3337375C303030445C303030695C303030735C303030635C303030755C303030735C303030735C303030695C3030306F5C3030306E}
\citation{bokhorst2015compliance}
\citation{carvalho,inoue2018comparative}
\@writefile{toc}{\contentsline {section}{\numberline {6}Discussion}{13}{section.6}\protected@file@percent }
\newlabel{sec:discussion}{{6}{13}{Discussion}{section.6}{}}
\@writefile{lof}{\contentsline {figure}{\numberline {6}{\ignorespaces \textbf  {Number of biopsies and the time delay in detecting cancer progression for various biopsy schedules} obtained via a simulation study. \textbf  {Mean} is indicated by the orange circle. Time delay (years) is calculated as (time of positive biopsy - the actual simulated time of cancer progression). Biopsies are conducted until cancer progression is detected. \textbf  {Panel\nobreakspace  {}A:} simulated patients who obtained cancer progression in the ten year study period (progressing). \textbf  {Panel\nobreakspace  {}B:} simulated patients who did not obtain cancer progression in the ten year study period (non-progressing). Types of schedules: ${\kappa =10\%}$ and $\kappa ^*(v)$ schedule a biopsy if the cumulative-risk of cancer progression at the current visit time $v$ is more than 10\%, and an automatically chosen threshold\nobreakspace  {}(\ref  {eq:kappa_choice}), respectively. Schedule ${\kappa ^*\{v \mid E(\mathcal  {D})\leq 0.75\}}$ is similar to $\kappa ^*(v)$ except that the euclidean distance in\nobreakspace  {}(\ref  {eq:kappa_choice}) is minimized under the constraint that expected delay in detecting progression is at most 9 months (0.75 years). Annual corresponds to a schedule of yearly biopsies, and PRIAS corresponds to biopsies as per PRIAS protocol (Section\nobreakspace  {}\ref  {sec:results}).\relax }}{14}{figure.caption.6}\protected@file@percent }
\newlabel{fig:figure6}{{6}{14}{\textbf {Number of biopsies and the time delay in detecting cancer progression for various biopsy schedules} obtained via a simulation study. \textbf {Mean} is indicated by the orange circle. Time delay (years) is calculated as (time of positive biopsy - the actual simulated time of cancer progression). Biopsies are conducted until cancer progression is detected. \textbf {Panel~A:} simulated patients who obtained cancer progression in the ten year study period (progressing). \textbf {Panel~B:} simulated patients who did not obtain cancer progression in the ten year study period (non-progressing). Types of schedules: ${\kappa =10\%}$ and $\kappa ^*(v)$ schedule a biopsy if the cumulative-risk of cancer progression at the current visit time $v$ is more than 10\%, and an automatically chosen threshold~(\ref {eq:kappa_choice}), respectively. Schedule ${\kappa ^*\{v \mid E(\mathcal {D})\leq 0.75\}}$ is similar to $\kappa ^*(v)$ except that the euclidean distance in~(\ref {eq:kappa_choice}) is minimized under the constraint that expected delay in detecting progression is at most 9 months (0.75 years). Annual corresponds to a schedule of yearly biopsies, and PRIAS corresponds to biopsies as per PRIAS protocol (Section~\ref {sec:results}).\relax }{figure.caption.6}{}}
\citation{balasubramanian2003estimation}
\citation{coley2017prediction}
\BKM@entry{id=18,open,dest={73656374696F6E2E36},srcline={291}}{5C3337365C3337375C303030415C303030635C3030306B5C3030306E5C3030306F5C303030775C3030306C5C303030655C303030645C303030675C3030306D5C303030655C3030306E5C303030745C30303073}
\BKM@entry{id=19,open,dest={73656374696F6E2E36},srcline={311}}{5C3337365C3337375C303030445C303030615C303030745C303030615C3030305C3034305C303030415C303030765C303030615C303030695C3030306C5C303030615C303030625C303030695C3030306C5C303030695C303030745C30303079}
\BKM@entry{id=20,open,dest={73656374696F6E2E36},srcline={314}}{5C3337365C3337375C303030535C303030755C303030705C303030705C3030306C5C303030655C3030306D5C303030655C3030306E5C303030745C303030615C303030725C303030795C3030305C3034305C303030695C3030306E5C303030665C3030306F5C303030725C3030306D5C303030615C303030745C303030695C3030306F5C3030306E}
\bibdata{bibliography}
\@writefile{toc}{\contentsline {section}{Acknowledgments}{15}{section.6}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{Data Availability}{15}{section.6}\protected@file@percent }
\BKM@entry{id=21,open,dest={73656374696F6E2E36},srcline={1}}{5C3337365C3337375C303030525C303030655C303030665C303030655C303030725C303030655C3030306E5C303030635C303030655C30303073}
\bibcite{world2014global}{{1}{}{{}}{{}}}
\bibcite{bokhorst2015compliance}{{2}{}{{}}{{}}}
\bibcite{weusten2017endoscopic}{{3}{}{{}}{{}}}
\bibcite{krist2007timing}{{4}{}{{}}{{}}}
\bibcite{mcwilliams2008surveillance}{{5}{}{{}}{{}}}
\bibcite{loeb2013systematic}{{6}{}{{}}{{}}}
\bibcite{LeClercq2015325}{{7}{}{{}}{{}}}
\bibcite{alagoz2010operations}{{8}{}{{}}{{}}}
\bibcite{steimle2017markov}{{9}{}{{}}{{}}}
\bibcite{vickers2006decision}{{10}{}{{}}{{}}}
\bibcite{tomer2019personalizedbiometrics}{{11}{}{{}}{{}}}
\bibcite{bebu2017optimal}{{12}{}{{}}{{}}}
\bibcite{rizopoulos2015personalized}{{13}{}{{}}{{}}}
\bibcite{tomer2019personalized}{{14}{}{{}}{{}}}
\bibcite{wang2019learning}{{15}{}{{}}{{}}}
\bibcite{tsiatis2004joint}{{16}{}{{}}{{}}}
\bibcite{rizopoulos2012joint}{{17}{}{{}}{{}}}
\bibcite{mcculloch2005generalized}{{18}{}{{}}{{}}}
\bibcite{loeb2014overdiagnosis}{{19}{}{{}}{{}}}
\bibcite{epsteinGG2014}{{20}{}{{}}{{}}}
\@writefile{toc}{\contentsline {section}{Supplementary information}{16}{section.6}\protected@file@percent }
\@writefile{toc}{\contentsline {section}{References\markboth  {\MakeUppercase  {References}}{\MakeUppercase  {References}}}{16}{section.6}\protected@file@percent }
\bibcite{loeb2014heterogeneity}{{21}{}{{}}{{}}}
\bibcite{GlobalCancerStats2012}{{22}{}{{}}{{}}}
\bibcite{brown2009assessing}{{23}{}{{}}{{}}}
\bibcite{taylor2013real}{{24}{}{{}}{{}}}
\bibcite{eilers1996flexible}{{25}{}{{}}{{}}}
\bibcite{cook1994equivalence}{{26}{}{{}}{{}}}
\bibcite{sassi2006calculating}{{27}{}{{}}{{}}}
\bibcite{de2017should}{{28}{}{{}}{{}}}
\bibcite{rizopoulosJMbayes}{{29}{}{{}}{{}}}
\bibcite{landmarking2017}{{30}{}{{}}{{}}}
\bibcite{carvalho}{{31}{}{{}}{{}}}
\bibcite{inoue2018comparative}{{32}{}{{}}{{}}}
\bibcite{balasubramanian2003estimation}{{33}{}{{}}{{}}}
\bibcite{coley2017prediction}{{34}{}{{}}{{}}}
\FirstPg{0}\LastPg{16}
\providecommand\NAT@force@numbers{}\NAT@force@numbers
\gdef \@abspage@last{17}
